Business Context and Reporting Period
This Form 8-K was filed by Ra Medical Systems, Inc. (not Catheter Precision, Inc.) on September 27, 2019. The report discloses a voluntary recall of the company's DABRA laser system single-use catheters due to inconsistent performance and a change in product labeling.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed relates to the specific event:
- Estimated Recall Costs: Between $0.2 million and $0.4 million.
Material Changes and Event Details
The company initiated a voluntary recall of DABRA catheters at customer sites to replace them with units displaying a new label. Key details include:
- Root Cause: Catheters more than two months from sterilization had a significantly higher rate of non-calibration compared to those within two months.
- Labeling Change: The shelf life expiration is being reduced from twelve months to two months.
- Operational Impact: The recall aims to reduce calibration failures and improve customer satisfaction. The company is notifying physician customers and arranging product returns.
Outlook, Risks, and Management Commentary
Management is continuing to review and upgrade manufacturing processes with the goal of extending the reliable calibration period and shelf life beyond two months in the future. The filing highlights several material risks:
- Regulatory Risk: The FDA may disagree with the proposed two-month shelf life, require an additional recall, mandate a shorter shelf life, or order a cessation of manufacturing/marketing.
- Legal Risk: The recall could subject the company to claims or proceedings that may adversely impact its business and financial condition.
- Execution Risk: Uncertainty regarding the ability to replace affected catheters in a timely and effective manner.
Investor Verification Checklist
- Verify the actual financial impact of the recall against the estimated $0.2–$0.4 million range in upcoming quarterly reports.
- Monitor FDA communications regarding the acceptance of the new two-month shelf life label.
- Assess whether the manufacturing process upgrades successfully extend the shelf life beyond two months as planned.
- Review subsequent filings for any customer claims or legal proceedings arising from the recall.